Pembrolizumab is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes. The FDA initially approved it to treat metastatic melanoma.
Secukinumab; Infliximab; Ramucirumab; Ipilimumab; Atezolizumab; Daratumumab; Dulaglutide; Rituximab; Adalimumab; Nivolumab; Denosumab; Cetuximab; Bevacizumab; Aflibercept
Copyright Copyright (C) 2018-2021 Taizhou Crene Biotechnology Co.,Ltd.
Address:Economic Developed Zone of Taizhou Zhejiang China